NCT03930485

Brief Summary

The primary aim of this study is to determine whether the prevalence of neuroticism, anxiety and body vigilance is higher in patients diagnosed with PPPD compared to those who suffered a vestibular insult but did not develop PPPD and healthy controls. An increased prevalence of one or more of these factors may identify them as risk factors in the development of PPPD. The secondary aim is to understand how PPPD affects quality of life.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 9, 2019

Completed
Same day until next milestone

Study Start

First participant enrolled

April 9, 2019

Completed
20 days until next milestone

First Posted

Study publicly available on registry

April 29, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2020

Completed
Last Updated

December 22, 2020

Status Verified

December 1, 2020

Enrollment Period

10 months

First QC Date

April 9, 2019

Last Update Submit

December 21, 2020

Conditions

Outcome Measures

Primary Outcomes (3)

  • Scores of the Generalised Anxiety & Depression - 7 (GAD-7) questionnaire

    Average total scores of the GAD-7 will be compared across each study group. Higher scores indicate higher feelings of anxiety and/or depression in that study group. The minimum score is 0 and the maximum is 21.

    1 year

  • Scores of the Big Five Inventory (BFI) questionnaire

    Average total scores for each category of the BFI will be compared across each study group. The BFI measures five personality areas: Extraversion, Aggreableness, Conscientiousness, Neuroticism, and Openess. Minimum scores for each subcategory is 1 and the maximum is 5. Higher scores indicate a higher propensity for that personality trait.

    1 year

  • Scores from the Body Vigilance Scale (BVS) questionnaire

    Average scores for each question of the BVS will be compared across each study group. Minimum score is 0, maximum score is 10. Higher scores indicate higher body vigilance towards bodily sensations.

    1 year

Secondary Outcomes (3)

  • Scores from the Dizziness Handicap Inventory (DHI) questionnaire

    1 year

  • Scores from the Vertigo Symptom Scale (VSS) questionnaire

    1 year

  • Scores from the Brief Dizziness Perception Questionnaire (DPQ)

    1 year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients who have been given a previous diagnosis of PPPD will be considered as potential cases and screened for inclusion/exclusion criteria. PPPD diagnosis must be based on the CCBS criteria (Table 1). Participants will be identified by a member of the current clinical care team either through clinic notes or in the outpatient clinics.

You may qualify if:

  • Must have diagnosis of PPPD based on the CCBS criteria
  • Aged under 18 years old

You may not qualify if:

  • No confirmed/firm diagnosis of PPPD
  • Aged \<18 years old
  • Unable to provide informed consent
  • Current clinically significant illness that could confound the study results

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Southend Hospital

Westcliff-on-Sea, Essex, SS0 0RY, United Kingdom

Location

MeSH Terms

Conditions

Dizziness

Condition Hierarchy (Ancestors)

Sensation DisordersNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Aaron Trinidade, MBBS

    CI

    PRINCIPAL INVESTIGATOR
  • Bhaskar Dasgupta, MD

    R&D Director

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 9, 2019

First Posted

April 29, 2019

Study Start

April 9, 2019

Primary Completion

January 31, 2020

Study Completion

January 31, 2020

Last Updated

December 22, 2020

Record last verified: 2020-12

Data Sharing

IPD Sharing
Will not share

Locations